These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25459673)

  • 21. [Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein].
    Chen Z; Liang H; Zhang X; Wang X; Chen W; Shi X; Yi C; Rao L
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1615-9. PubMed ID: 23174588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
    Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
    World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in rat models with hepatocellular carcinoma with liver cirrhosis.
    Park SI; Lee JH; Ham HJ; Jung YJ; Park MS; Lee J; Maeng LS; Chung YA; Jang KS
    Biomed Mater Eng; 2015; 26 Suppl 1():S1669-76. PubMed ID: 26405933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas.
    Noda Y; Kanematsu M; Goshima S; Suzui N; Hirose Y; Matsunaga K; Nishibori H; Kondo H; Watanabe H; Kawada H; Kawai N; Tanahashi Y; Bae KT
    Eur Radiol; 2015 Oct; 25(10):3009-16. PubMed ID: 25854217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
    Kim JW; Seong J; Yun M; Lee IJ; Yoon HI; Cho HJ; Han KH
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1172-8. PubMed ID: 21570203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET/Computed Tomography in Evaluation of Transarterial Chemoembolization.
    Ortega López N
    PET Clin; 2015 Oct; 10(4):507-17. PubMed ID: 26384597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT.
    Hwang SH; Lee M; Lee N; Park S; Kim CK; Park MA; Yun M
    Clin Nucl Med; 2016 Apr; 41(4):296-301. PubMed ID: 26756099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined early dynamic (18)F-FDG PET/CT and conventional whole-body (18)F-FDG PET/CT provide one-stop imaging for detecting hepatocellular carcinoma.
    Wang SB; Wu HB; Wang QS; Zhou WL; Tian Y; Li HS; Ji YH; Lv L
    Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):324-30. PubMed ID: 25487755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
    Pant V; Sen IB; Soin AS
    Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
    Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Pathologic Grade and Prognosis in Mucoepidermoid Carcinoma of the Lung Using ¹⁸F-FDG PET/CT.
    Park B; Kim HK; Choi YS; Kim J; Zo JI; Choi JY; Shim YM
    Korean J Radiol; 2015; 16(4):929-35. PubMed ID: 26175595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT].
    Zhao M; Wu PH; Zeng YX; Zhang FJ; Huang JH; Fan WJ; Gu YK; Zhang L; Tan ZB; Lin YE
    Ai Zheng; 2005 Sep; 24(9):1118-23. PubMed ID: 16159437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and
    Rhee WJ; Hwang SH; Byun HK; Yun M; Han KH; Seong J
    Liver Int; 2017 Apr; 37(4):592-599. PubMed ID: 27804192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
    Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT.
    Hartenbach M; Weber S; Albert NL; Hartenbach S; Hirtl A; Zacherl MJ; Paprottka PM; Tiling R; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1661-6. PubMed ID: 26405170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.